{"id":38126,"key":"Global_Health_Medical_Device_Compendium/Prove-It_Sepsis_Strip_Array","title":"Global Health Medical Device Compendium/Prove-It Sepsis Strip Array","latest":{"id":1267383,"timestamp":"2026-09-10T13:12:09Z"},"content_model":"wikitext","license":{"url":"https://www.appropedia.org/Appropedia:Copyrights","title":"CC-BY-SA-4.0"},"source":"[[File:Prove it sepsis strip.jpg|thumb]]\n\n{{GHMDC device data\n| health-topic = Maternal mortality\n| classification = Diagnosis\n| scope = Commercialized\n| made = No\n| replicated = No\n| manufacturer-location = Helsinki, Finland\n}}\n\nInfection is a large contributor to maternal mortality and morbidity in developing countries. Nearly one third of all maternal deaths are attributed to infection, which can easily be prevented by minor improvements in sterile child delivery practices and reduction of bacterial transmission. Additionally, improvements in the diagnosis of sepsis can help improve mortality rates as well.\n\n== Detailed description of the solution ==\n\nThis sepsis identification method uses a new microarray platform that determines the type of bacteria through the use of antibiotics. The \"microarray platform is a series of microscopic spots of short DNA fragments whose sequences are specific for individual organisms.\" Prove-It is highly accurate and produces results faster than the current gold standard by 18 hours, allowing for rapid and effective treatment of the infection. It is able to detect more than 60 species of gram negative and gram positive bacteria that most frequently cause sepsis. Additionally, the test can identify 13 fungal pathogens and antibiotic resistance markers.\n\n== Designed by ==\n\n* Designed by: Mobidiag Ltd, Finland, MGRADE (Roche Diagnostics)\n* Manufacturer location:\n\nHelsinki, Finland (Distributors throughout Europe and Middle East: http://www.mobidiag.com/Order/LocalDistributors/tabid/183/Default.aspx\n\n== When and where it was tested/implemented ==\n\nThe device has mainly been tested in laboratory settings, where it is generally expected to be used.\n\n== References ==\n\n=== Peer-reviewed publication ===\n\nAllais, E., Boisset, S. et al (2009). 'Use of a new and simple microarray assay (Prove-itTM Sepsis) for rapid identification of bacteria involved in bone and joint infections directly from clinical samples', Clinical Microbiology and Infection, 15, S279.\n\nTissari, P., Zumla, A. et al (2010). Accurate and rapid identification of bacterial species from positive blood cultures with a DNA-based microarray platform: an observational study, The Lancet, 375(9710), 224-230.\n\nYoo, S. M. & Lee, S. Y. (2010). DNA microarray for the identification of pathogens causing bloodstream infections. Expert Rev Mol Diagn, 10(3), 263- 268.\n\nLehmann, L. E., Hunfeld, K. P. et al (2010). Improved detection of blood stream pathogens by real-time PCR in severe sepsis. Intensive Care Med, 36(1), 49-56.\n\nPeters, Remco PH, Paul HM Savelkoul, and Christina MJE Vandenbroucke-Grauls. (2010). Future Diagnosis of Sepsis. The Lancet, 375(9728), 1779-780.\n\n=== Other internally generated reports ===\n\nMobidiag Ltd (2009). Prove-it™ Sepsis. Retrieved Nov 13, 2011, from http://www.mobidiag.com/Products/ProveittradeSepsis/tabid/60/Default.aspx\n\n=== Externally generated reports ===\n\nEuroScan International Network. (2011, March 4). Rapid Molecular Assays for the Diagnosis of Sepsis and Identification of Sepsis Causing Pathogens. Retrieved November 13, 2011, from http://www.euroscan.org.uk/technologies/technology/ view/1594\n\n=== IP and copyright ===\n\nMobidag currently owns a patent on this product.\n\n{{Page data\n| sdg = SDG03 Good health and well-being, SDG09 Industry innovation and infrastructure\n| license = CC-BY-SA-3.0\n| language = en\n}}"}